Illustration of a child protected from bacteria during leukemia treatment.

Battling Bacteria: Understanding Infections in Childhood Leukemia Treatment

Lena Kashyap monogram
Lena Kashyap in Health & Wellness October 2026 • 4 min read.

"A deep dive into bacterial infections during acute lymphoblastic leukemia (ALL) therapy and strategies for improving patient outcomes."


Chemotherapy is a critical treatment for acute lymphoblastic leukemia (ALL) in children. However, this intensive treatment phase, typically lasting about six months, weakens the immune system, making young patients highly susceptible to infections. This increased vulnerability stems from neutropenia (low white blood cell count) and impaired B and T cell function, both consequences of leukemia and its treatment.

Bacterial infections are a significant concern during ALL therapy, potentially leading to severe complications and impacting overall survival rates. Understanding the incidence, types, and effects of these infections is crucial for optimizing treatment strategies and improving patient outcomes.

This article explores the challenges of bacterial infections in children undergoing intensive chemotherapy for ALL, based on findings from a retrospective study. It delves into the prevalence of these infections, the causative bacterial organisms, their impact on mortality, and the implications for clinical practice.

AI Search Multiple angles on this topic

Bacterial Infections During Leukemia Treatment

Bacterial infections are a major part of the documented infections in children and adolescents with hematological malignancies, with bloodstream infections among the most frequent sciencedirect.com. A study described in 2026 notes that children with acute leukemia are at risk of bacteremia because of their disease and treatment-related toxicities, while also highlighting limited data on how bacterial pathogens vary across infants, children, and adolescents journals.plos.org. The provided source material does not report infection rates or mortality figures.

Profiling Pathogens and Resistance

A study of 30 pediatric leukemia patients aged 1–16 years investigated bacterial causes of infection and antibiotic resistance pmc.ncbi.nlm.nih.gov. It identified 13 pathogens: 8 Gram-positive and 5 Gram-negative bacteria mdpi.com. The supplied excerpts do not describe a standard treatment protocol or provide enough detail to assess the limitations of particular treatment methods.

The Challenge of Bacterial Infections in ALL Treatment

Illustration of a child protected from bacteria during leukemia treatment.

A retrospective study was conducted on 834 children (247 girls and 587 boys) diagnosed with ALL and treated at the Christian Medical College (CMC) Vellore between 2006 and 2016. The analysis revealed important insights into the occurrence and nature of bacterial infections during their treatment. The children were risk-stratified into three groups: standard risk (15%), intermediate risk (80.9%), and high risk (4.1%).

The study found that bacterial infections occurred in 117 (14%) of the patients. Among these infections:

  • Gram-negative bacteria were responsible for 66.6% of the infections.
  • Gram-positive bacteria caused 47% of the infections.
  • A dual blood culture positivity was observed in 11% of the patients.
AI Search Multiple angles on this topic

Evidence on Treatment Challenges

The cited source describes a study investigating bacterial causes and antibiotic resistance in pediatric leukemia patients, with the aim of examining how chronic pathology may affect treatment efficacy. The supplied excerpt provides no results, resistance figures, or documented examples of treatment failure. It therefore does not establish how often treatment fails or which approaches are ineffective.

Among children with gram-negative infections, the most common organisms identified were Klebsiella (32%), Pseudomonas (30.7%), NFGNB (19.2%), and E. coli (17.9%). Sensitivity patterns indicated that 29.4% of organisms were pansensitive, while extended spectrum beta lactamase (ESBL) growth was seen in 52.5%, and carbapenem-resistant organisms (CRO) in 15.3%. This highlights the increasing challenge of antibiotic resistance in treating these infections.

Improving Outcomes: Addressing Bacterial Infections in ALL Therapy

The study highlighted a significant finding: the mortality rate due to bacterial infection was 14.5%. Moreover, the overall survival (OS) at 6 months was significantly lower in patients who experienced bacterial infections compared to those who did not.

AI Search Multiple angles on this topic

Persistent Infection Risks

Despite improved survival rates for childhood leukemia, infections—particularly bacterial and fungal infections—remain a significant concern, especially during intensive treatment phases sciencedirect.com. The cited review summary identifies older children, delayed response during early induction therapy, and corticosteroid administration as factors associated with high risk ejcped.com. The supplied material also notes a systematic review focused on bacterial bone and joint infections in children with leukemia or undergoing allogeneic stem cell transplantation sciencedirect.com.

These findings underscore the critical need for proactive strategies to prevent and manage bacterial infections in children undergoing ALL therapy. This includes:

<ul><li>Implementing stringent infection control measures in healthcare settings.</li><li>Utilizing prophylactic antibiotics and antifungal medications judiciously.</li><li>Ensuring prompt diagnosis and treatment of infections based on sensitivity patterns.</li></ul>Further research is warranted to explore novel approaches for preventing and treating bacterial infections in this vulnerable population, ultimately improving survival rates and quality of life for children undergoing ALL treatment.

How other studies measured infection and mortality

  • 53.2% of childrenA separate study reported microbiologically documented bacterial infections in 53.2% of children with ALL during chemotherapy.[1]

What infection context adds to the leukemia findings

The cited clinical context describes bloodstream infections as especially serious during chemotherapy-related neutropenic fever. This helps explain why infection outcomes matter, but it does not establish the cause of any individual death in the article’s cohort.[2]

The contextual sources point to several vulnerabilities—neutropenia, disrupted mucosal barriers, and central venous catheters—rather than a single pathway to bacterial infection.[3] [4]

How related pediatric studies frame the results

A separate ALL chemotherapy study reported microbiologically documented bacterial infections, while another reported deaths mainly due to fungal infection; their outcomes are not directly interchangeable with the article’s bacterial-infection mortality measure.[1]

A pediatric oncology and transplant study found a higher mortality proportion among patients with bloodstream infections than among those without them. That association provides context, but it does not by itself establish that bloodstream infection caused the difference or that the same pattern applies to this article’s cohort.[5]

Other cited clinical sources describe neutropenic fever and reduced neutrophil activity as relevant to infection severity, and identify catheters and mucosal injury among infection risk factors. These are general clinical context, not findings measured in the article’s cohort.[2] [3] [4]

What remains unclear about this cohort

  • How much did bloodstream infection contribute to deaths in the article’s cohort, compared with other infection types?[1] [5]

Sources

  1. Infectious profile in children with ALL during chemotherapy: A report of study group for infections. (pubmed.ncbi.nlm.nih.gov)
  2. Supportive methods for childhood acute lymphoblastic leukemia then and now: A compilation for clinical practice (www.frontiersin.org)
  3. Neutropenia and Infection Prophylaxis in Childhood Cancer (pmc.ncbi.nlm.nih.gov)
  4. Risk factors for bacteremia in children with febrile neutropenia (pmc.ncbi.nlm.nih.gov)
  5. Mortality in pediatric oncology and stem cell transplant patients with bloodstream infections (pmc.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

This article is based on research published under:

DOI-LINK: 10.1016/j.phoj.2018.11.053, Alternate LINK

Title: Bacterial Infections In Children During Intensive Phase Of Treatment For Acute Lymphoblastic Leukaemia Therapy And Its Impact On Mortality

Subject: Oncology

Journal: Pediatric Hematology Oncology Journal

Publisher: Elsevier BV

Authors: Wanve Balasaheb, Anu Korula, Anup J. Devasia, Kavitha Nl, Uday P. Kulkarni, Aby Abraham, Alok Srivastava, Vikram Mathews, Biju George

Published: 2018-01-01

Everything You Need To Know

1

Why are bacterial infections a significant problem for children undergoing Acute Lymphoblastic Leukemia (ALL) treatment?

During Acute Lymphoblastic Leukemia (ALL) therapy, children often experience weakened immune systems. This vulnerability arises from neutropenia (low white blood cell count) and impaired B and T cell function, both results of the leukemia itself and the chemotherapy treatment. The weakened immune system makes children highly susceptible to bacterial infections.

2

What are the potential consequences of bacterial infections in children with Acute Lymphoblastic Leukemia (ALL)?

Bacterial infections are a major concern for children undergoing Acute Lymphoblastic Leukemia (ALL) therapy because they can lead to severe complications. These infections can also significantly impact overall survival rates. A study found that 14.5% of patients died due to bacterial infections, and the overall survival at 6 months was lower in patients who had infections.

3

What types of bacteria commonly cause infections in children undergoing Acute Lymphoblastic Leukemia (ALL) therapy?

In children undergoing Acute Lymphoblastic Leukemia (ALL) treatment, the most common bacterial infections involved Gram-negative bacteria. Specifically, Klebsiella, Pseudomonas, NFGNB, and E. coli were frequently identified. The study revealed that 66.6% of infections were attributed to Gram-negative bacteria, while Gram-positive bacteria caused 47% of the infections.

4

What does the study reveal about antibiotic resistance in the context of these infections?

The study on children with Acute Lymphoblastic Leukemia (ALL) indicated the increasing challenge of antibiotic resistance. Sensitivity patterns showed that while 29.4% of the organisms were pansensitive, extended spectrum beta lactamase (ESBL) growth was observed in 52.5%, and carbapenem-resistant organisms (CRO) were present in 15.3% of the cases. This resistance complicates treatment and can affect patient outcomes.

5

What were the key findings and the scope of the study regarding bacterial infections in children with Acute Lymphoblastic Leukemia (ALL)?

The retrospective study included 834 children diagnosed with Acute Lymphoblastic Leukemia (ALL) treated at Christian Medical College (CMC) Vellore between 2006 and 2016. The children were risk-stratified into standard risk (15%), intermediate risk (80.9%), and high risk (4.1%). The study examined the prevalence of bacterial infections, the specific bacteria involved (such as Klebsiella and Pseudomonas), the impact on mortality, and the implications for clinical practice.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.